Orion stock pops after raising 2025 outlook on Nubeqa momentum

Orion, the pharmaceutical company, upgraded its 2025 financial outlook, driven by stronger-than-expected performance from its cancer drug Nubeqa. The company raised its 2025 net sales guidance to €1,630m-€1,730m and its EBIT outlook to €400m-€500m, with these new targets now exceeding current market consensus. While Orion's stock saw a modest 1.5% intraday gain, analysts noted the lukewarm reaction likely reflects high investor expectations, though they see scope for further upside given the improved guidance and potential for an earlier-than-expected €180 million milestone payment from Bayer related to Nubeqa sales in 2025.

Analysis

Orion has materially upgraded its 2025 financial outlook, citing accelerated sales and royalty income from its cancer drug, Nubeqa. The company now projects net sales of €1,630m-€1,730m and operating profit (EBIT) of €400m-€500m, placing the new targets above current consensus estimates of €1,642m for sales and €431m for EBIT. This revision implies a potential consensus EBIT upgrade of approximately 16%, a significant fundamental improvement. Despite this strong guidance, the stock's intraday gain was a modest 1.5%, a reaction Jefferies analysts attribute to pre-existing high investor expectations. A key potential catalyst remains the €180 million milestone payment from partner Bayer, which could be recognized in 2025 instead of 2026; however, this upside is not yet factored into the official guidance due to timing uncertainty, suggesting further room for positive surprises.

Key Decisions for Investors

• Investors should evaluate the disconnect between the significant guidance upgrade, particularly the potential 16% EBIT consensus revision, and the muted 1.5% stock price reaction, as it may signal an under-appreciation of the news by the market.
• Monitor communications from both Orion and its partner Bayer for any updates on Nubeqa sales momentum, as the acceleration of the €180 million milestone payment into 2025 represents a material, un-priced catalyst.
• Consider that even with high investor expectations already priced in, the fundamental strength demonstrated by the guidance raise and the optionality of the milestone payment could provide further upside, warranting a review of current valuation models.